Search PubMed⌕ Search

Biomedical subjects

N I Gromnatskiĭ

Publications and source records attributed to N I Gromnatskiĭ.

At least 19 recordsLinked to original sources
PubMed2006

[Correction of thrombocyte-vascular hemostasis in metabolic syndrome].

The purpose of the study was to evaluate the therapeutic effects of lovastatin and allicor on thrombocyte-vascular hemostasis in patients suffering from arterial hypertension (AH) with metabolic syndrome (MS). Twenty-two patients were administered lovastatin in a dose of 20 mg before sleep; 23 patients received allicor in a dose of two tablets or 150 mg twice a day. The therapy lasted one month in both groups. The dynamics of the following variables was evaluated: anthropometric parameters, blood lipid spectrum, lipid peroxidation in serum and thrombocytes, the antioxidative protectability of the lipid part of blood and thrombocytes, thrombocyte aggregation and their intravascular activity, and vascular hemostasis indices. The results were processed using Student coefficient, as well as system and correlation analysis. The study shows that lovastatin and, to a less degree, allicor, has a hypolipidemic effect, as well as a positive effect on peroxidation syndrome in patients suffering from AH with MS, optimizing thrombocyte-vascular hemostasis to the same degree. As a cheaper drug, allicor may be used widely to prevent thrombosis in patients with AH with MS. In order to lessen body mass in such patients, lovastatin and allicor should be applied together with non-drug means.

Adult↗
PubMed2006

[The influence of hypocaloric diet on thrombocyte rheology in patients with metabolic syndrome].

The purpose of the study was to investigate the effects of hypocaloric diet (HCD) on intravascular thrombocyte activity (ITA) dynamics in patients with arterial hypertension (AH), androidal type of obesity, and glucose tolerance disorder. The subjects were 25 middle age patients with AH with metabolic syndrome (MS). Anthropometric variables, plasmatic lipid indices, as well as the intensity of lipid peroxidation in blood plasma and thrombocytes, were measured and evaluated. The patients' condition was being corrected using HCD during 24 weeks. The use of HCD in patients suffering from AH with metabolic syndrome favored lowering of the blood lipid spectrum shifts, suppression of peroxidation syndrome, and improvement of plasmatic and thrombocyte parameters. HCD lowered ITA, which was especially prominent by the end of the 24th week, but the control values were not reached. HCD in not effective enough as a sole method of correcting metabolic processes and ITA in patients suffering from AH with MS. Other therapeutic approaches to treatment of such patients should be searched.

Blood Platelets↗
PubMed2005

[Effect of amlodipine on intravascular thrombocyte activity in patients with arterial hypertension and metabolic syndrome].

In order to evaluate therapeutic effects of amlodipine on intravascular thrombocyte activity (ITA) in patients having arterial hypertension (AH) with metabolic syndrome (MS), 20 patients were treated with amlodipine for 1 month. The researchers monitored changes in anthropometric indices, blood lipid spectrum, lipid peroxidation in serum and thrombocytes, anti-oxidant protectability of platelets and the liquid part of blood and ITA. Amlodipine application in patients having AH with MS reduced peroxidation syndrome and optimized thrombocyte aggregation. Long-term administration of amlodipine stabilizes the achieved effect. To lower body weight in patients having AH with MS administration of amlodipine should be combined with use of non-drug means.

Adult↗
PubMed2005

[Normodipin in correction of platelet rheology in hypertensive patients with metabolic syndrome].

AIM: To determine a therapeutic effect of normodipin on intravascular platelet activity in patients with arterial hypertension (AH) and metabolic syndrome (MS). MATERIAL AND METHODS: Twenty patients received normodipin for one month in a dose 10 mg/day. The drug activity was assessed by dynamics of anthropometric indices, lipid spectrum of the blood, lipid peroxidation in plasma and platelets, antioxidant protection of blood liquid and platelets, intravascular platelet activity. The results were processed statistically. RESULTS: Normodipin in hypertensive patients with MS has a positive effect on peroxidation and platelet aggregation. Long-term normodipin administration promoted stabilization of the effect. CONCLUSION: To reduce body mass in hypertensive patients with MS it is necessary to combine normodipin administration with nonpharmacological medication.

Amlodipine↗
PubMed2005

[Correction of thrombocyte hemostasis and biological age reduction in metabolic syndrome].

The study shows that application of metformin, hypocaloric diet, and rational physical loads in patients with arterial hypertension (AH) with metabolic syndrome and impaired glucose tolerance (IGT), reduces pathologically hightened biological age (BA), eliminating shifts in blood lipid spectrum, moderating peroxidation syndrome, and reducing changes in thrombocyte homeostasis. Such complex therapy normalizes the adhesive and aggregation function of thrombocytes in vitro, and their intravascular activity. The parameters of the subjects had approximated the control level by the end of the 24th week of treatment. To reduce the biological age down to the level of chronological one, stabilize metabolic processes and thrombocyte homeostasis in patients with AH and IGT, the offered therapy should be prolonged and controlled.

Aging↗
PubMed2004

[Thrombocytic hemostasis in hypertensive patients with metabolic syndrome and its correction with lovastatin].

The objective of the study was to evaluate the efficiency of lovastatin correction of dyslipidemia and impaired intravascular platelet activity (IPA) in patients with arterial hypertension (AH) concurrent with metabolic syndrome (MS). Eighteen patients were given lovastatin for a month. The time course of changes in anthropometric parameters, blood lipid spectrum, plasma and lipid peroxidation, antioxidative protectiveness of the liquid blood part and platelets, and IPA were assessed. The results were processed by Student's test and correlation analysis. Lovastin was ascertained to correct dyslipoproteinemia and peroxidation syndrome and to optimize the intrathrombocytic mechanisms responsible for their function regulation in patients with AH + MS. Lovastatin inhibits in vivo increased platelet activity. These effects may be stabilized during its use. Body weight loss and diminished insulin resistance in patients with AH concurrent MS require long use of lovastatin along with low-calorie diet and exercises.

Anticholesteremic Agents↗
PubMed2003

[Non-pharmacological correction of impaired platelet hemostasis in hypertensive patients with metabolic syndrome].

Low-calorie diet and individually adjusted physical exercise used in combination in hypertensive patients with metabolic syndrome correct shifts in blood lipid spectrum, relieve peroxidation syndrome, normalize impaired platelet hemostasis, suppress enhanced adhesive and aggregation functions of platelets in vitro and their intravascular activity. The improvement reached maximum after 24 weeks of treatment but control values were not achieved. Therefore, for effective correction of metabolic processes and platelet hemostasis in hypertensive patients with disorder of glucose tolerance, non-pharmacological measures should be supplemented with pharmacological ones.

Blood Platelets↗
PubMed2002

[Effect of nebivolol on remodeling of the heart and vessels and the state of hemodynamics in patients with hypertension].

Echocardiography, doppler echocardiography and venous occlusion plethysmography were used for the study of effects of monotherapy with nebivolol (2.5-10, mean 5.1 mg/day for 24 weeks) on remodeling of cardiovascular system and the state of hemodynamics in 25 patients with stage II hypertension and chronic heart failure (NYHA class I-II). Treatment with nebivolol was associated with lowering of systolic and diastolic blood pressure (by 22% and 26%, respectively), significant reduction of left ventricular mass index, improvement of parameters of systolic and diastolic left ventricular function and lowering of NYHA class of heart failure. Favorable changes of remodeling of peripheral vessels and of endothelium-dependent vasodilatation also occurred.

Adrenergic beta-Antagonists↗
PubMed2000

[Hypolipidemic effects of alisat and lipostabil in patients with diabetes mellitus].

AIM: To study a hypolipidemic action of alisat and lipostabil in patients with non-insulin-dependent diabetes mellitus (NIDDM). MATERIAL AND METHODS: Changes in blood lipids were studied in 121 NIDDM patients aged 36-66 years with compensated or subcompensated carbohydrate metabolism on sugar-reducing therapy. The latter consisted of a 52-week course of alisat (600 mg/day) or lipostabil (900 mg/day) in baseline levels of total cholesterol (TC) under 6.5 mmol/l and above 6.5 mmol/l, respectively. RESULTS: Alisat and lipostal treatments reduced TC levels from 5.4 +/- 25 to 4.77 +/- 0.12 mmol/l and from 7.07 +/- 0.24 to 5.92 +/- 0.30, LDLP cholesterol from 4.0 +/- 0.31 to 2.98 +/- 0.15 mmol/l and 5.54 +/- 0.25 to 4.04 +/- 0.34 mmol/l, respectively. Lipostabil changed LDLP cholesterol and triglycerides from 0.51 +/- 0.05 to 0.33 +/- 0.03 mmol/l and from 2.54 +/- 0.25 to 1.66 +/- 0.15 mmol/l, respectively, while HDLP cholesterol rose from 1.22 +/- 0.10 to 1.55 +/- 0.07 mmol/l. Alisat did not change significantly. CONCLUSION: Adjuvant lipostabil is recommended in combined treatment of NIDDM in marked dyslipidemia, alisat--in moderate dyslipidemia.

Adult↗